Integrated Diagnostics Holdings PLC IDH appoints Group CFO, VP and Board Member (2011A)
18 Gennaio 2024 - 5:03PM
UK Regulatory
TIDMIDHC
RNS Number : 2011A
Integrated Diagnostics Holdings PLC
18 January 2024
IDH appoints Group CFO, VP and Board Member
18 January 2024
(Cairo and London) - Integrated Diagnostics Holdings ("IDH,"
"the Group," or "the Company"), a leading consumer clinical
laboratory, and one of the largest diagnostic players in the Middle
East and Africa, with operations in Egypt, Jordan, Nigeria, Sudan,
and Saudi Arabia, announces the appointment of Sherif El Zeiny as
Board Member, Vice President and Group Chief Financial Officer,
effective 18 January 2024. El Zeiny is a seasoned and certified
Board Director and Executive Partner, boasting over three decades
of experience in financial management, business leadership, and
corporate strategy. Previously, El Zeiny served as Vice President
and Group Chief Financial Officer at Elsewedy Electric.
Commenting on El Zeiny's appointment, Dr. Hend El Sherbini,
Group Chief Executive Officer, said: "On behalf of IDH's Board of
Directors and management team, I am excited to welcome Sherif on
board as Board Member, VP and Group CFO. Along with the entire IDH
team, I will prioritize ensuring a smooth and efficient transition
as Sherif fills his role and the Group focuses on expanding our
operations, growing our top-line, and improving our margins across
our geographies. I am confident that the extensive experience and
unique skill set that Sherif brings with him will prove vital to
our continued financial success moving forward."
Sherif El Zeiny, Group Chief Financial Officer, added: "I am
thrilled to join IDH in such a pivotal time in its history. I am
particularly excited about the Company's new venture into Saudi
Arabia, which will inevitably serve to widen its patient base and
cement its position as a regional leader in the diagnostics field.
With a firm belief that financial growth is the bedrock of any
successful business, I look forward to optimizing our resources,
making smart investments, and driving responsible growth under the
umbrella of strong corporate governance and digital transformation
to usher in another era of success for IDH and its
shareholders."
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading diagnostics services provider in the Middle
East and Africa offering a broad range of pathology and radiology
tests to patients in Egypt, Jordan, Nigeria, Sudan, and soon
launching in Saudi Arabia. The Group's core brands include Al Borg,
Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan),
Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab
(Nigeria). A long track record for quality and safety has earned
the Company a trusted reputation, as well as internationally
recognised accreditations for its portfolio of over 3,000
diagnostics tests. From its base of 552 branches as of 31 December
2022, IDH served over 8.7 million patients and performs more than
32.7 million tests in 2022. IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and East Asian markets where its model is
well-suited to capitalise on similar healthcare and consumer trends
and capture a significant share of fragmented markets. IDH has been
a Jersey-registered entity with a Standard Listing on the Main
Market of the London Stock Exchange (ticker: IDHC) since May 2015
with a secondary listing on the EGX since May 2021 (ticker:
IDHC.CA).
Learn more at idhcorp.com .
Contact
Tarek Yehia
Investor Relations Director
T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 |
tarek.yehia@idhcorp.com
LEI: 2138007JN9NUWKKTS790
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASFFFMAELSESF
(END) Dow Jones Newswires
January 18, 2024 11:03 ET (16:03 GMT)
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Dic 2023 a Dic 2024
